Related Experiment Video
Updated: Sep 9, 2025
14:36
Adult and Embryonic Skeletal Muscle Microexplant Culture and Isolation of Skeletal Muscle Stem Cells
Published on: September 21, 2010
28.9K
Human Mesenchymal Stem Cell-Derived Skeletal Muscle Cell Spheroids for Treating Dexamethasone-Induced Sarcopenia
Yoonji Yum1, Juhee Yoon1, Yu Hwa Nam1
1Department of Biochemistry, College of Medicine, Ewha Womans University, 25 Magokdong-ro-2-gil, Gangseo-gu, Seoul, Republic of Korea.
Tissue Engineering and Regenerative Medicine
|September 3, 2025
Summary
Tonsil-derived mesenchymal stem cell spheroids show promise for treating sarcopenia. Transplantation improved muscle function and regeneration in a rat model, offering a potential therapy for age-related muscle loss.
Area of Science:
- Regenerative Medicine
- Musculoskeletal Diseases
- Stem Cell Therapy
Background:
- Sarcopenia is characterized by reduced muscle mass, strength, and performance, often linked to aging.
- Dexamethasone (DEX)-induced muscular atrophy in animal models mimics sarcopenia.
- Mesenchymal stem cell (MSC) therapies, especially 3D cultured spheroids, are promising for muscle regeneration.
Purpose of the Study:
- To evaluate the therapeutic potential of tonsil-derived mesenchymal stem cell-derived skeletal muscle cell spheroids (TMSC-SKMC-spheroids) in a rat model of sarcopenia.
Main Methods:
- TMSC-SKMC-spheroids were generated using microwells and transplanted into DEX-induced muscular atrophy rat models.
- Therapeutic efficacy was assessed via grip strength, running fatigue tests, muscle measurements, and histopathology.
Main Results:
- Transplantation led to improved hind limb motor functions and gastrocnemius muscle regeneration.
- Neuromuscular junction restoration was observed in the gastrocnemius muscle of treated rats.
Conclusions:
- TMSC-SKMC-spheroids demonstrate therapeutic potential in a preclinical sarcopenia model.
- These spheroids represent a promising therapeutic resource for sarcopenia treatment.
